The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis

Background/aim: To investigate the impact of smoking on disease activity, treatment retention, and response in patients with ankylosing spondylitis (AS) treated with their first tumor necrosis factor-α inhibitor (TNFi). Materials and methods: AS patients who started their first TNFi treatment for the active axial disease (BASDAI ≥ 4) from TURKBIO Registry were included. Treatment response of smoker (current and ex-smokers) and nonsmoker (never smoker) patients were primarily evaluated as achievement of BASDAI50 or improvement in BASDAI at least 20 mm at 3 months and 6 months compared to baseline. Results: There were 322 patients with AS (60% male, 59% smoker, mean age: 38.3 years). The median follow-up time was 2.8 years (Q1– Q3: 1.3–3.8), and disease duration was 3.5 years (Q1–Q3: 0.7–8.2). Smokers had male predominance (p < 0.001), lower ESR (p = 0.03), higher BASDAI (p = 0.02), BASFI (p = 0.05), HAQ-AS (p = 0.007), and ASDAS-CRP (p = 0.04) compared with nonsmokers at baseline. In the multivariate analysis, male gender [OR 2.7 (95%CI 1.4–5), p = 0.002], and concomitant conventional synthetic disease-modifying antirheumatic drug use [OR 2.4 (95%CI 1.1–5.2), p = 0.03] were associated with better treatment response. There was an association of male gender [HR 2.4 (95%CI 1.6–3.7), p < 0.001], older age (≥30years) [HR 1.8 (95%CI 1.1–2.8), p = 0.01], and response to treatment [HR 1.8 (95%CI 1.2–2.9), p = 0.008] with better treatment retention. No impact of smoking status was found on treatment retention and response in univariate and multivariate analyses. Conclusion: This study suggested that smoking was associated with poorer patient-reported outcomes in biologic naïve AS patients initiating their first TNFi treatment, but it had no impact on the TNFi treatment response and retention rate.

Anahtar Kelime: Ankylosing spondylitis smoking tumor necrosis factor-alpha inhibitor treatment response registry

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Annals of the Rheumatic Diseases 2010; 69 (1): 70–81. https:// doi.org/10.1136/ard.2008.096487
2. Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology (Oxford) 2020; 59 (5): 29-38. https://doi. org/10.1093/rheumatology/keaa382.)
3. Videm V, Cortes A, Thomas R, Brown MA. Current Smoking is Associated with Incident Ankylosing Spondylitis — The HUNT Population-based Norwegian Health Study. The Journal of Rheumatology 2014; 41 (10) 2041-2048. https://doi. org/10.3899/jrheum.140353
4. Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H et al. Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort (GESPIC). Annals of the Rheumatic Diseases 2013; 72 (8): 1430-2. https://doi. org/10.1136/annrheumdis-2012-203148
5. Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis & Rheumatism 2012; 64 (5): 1388-98. https://doi. org/10.1002/art.33465
6. Maas F, Arends S, Wink FR, Bos R, Bootsma H et al. Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-alpha inhibitors. PLoS One 2017; 12 (6): e0177231. https://doi.org/10.1371/journal.pone.0177231
7. Chung HY, Machado P, van der Heijde D, D’Agostino MA, Dougados M. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Annals of the Rheumatic Diseases 2012; 71 (6): 809-16. https://doi.org/10.1136/ annrheumdis-2011-200180
8. Villaverde-Garcia V, Cobo-Ibanez T, Candelas-Rodriguez G, Seoane-Mato D, Campo-Fontecha PDD et al. The effect of smoking on clinical and structural damage in patients with axial spondyloarthritis: A systematic literature review. Seminars in Arthritis and Rheumatism 2017; 46 (5): 569-83. https://doi. org/10.1016/j.semarthrit.2016.11.004
9. Braun J, Davis J, Dougados M, Sieper J, van der Linden S et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases 2006; 65 (3): 316-20. https://doi.org/10.1136/ard.2005.040758
10. Poddubnyy D, Sieper J. What is the best treatment target in axial spondyloarthritis: tumour necrosis factor alpha, interleukin 17, or both? Rheumatology (Oxford) 2017; 57 (7) 1145–1150. https://doi.org/10.1093/rheumatology/kex361
11. Navarro-Compán V, Plasencia-Rodríguez C, de Miguel E, Diaz Del Campo P, Balsa A et al. Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review. Rheumatic & Musculoskeletal Diseases Open 2017; 3 (2): e000524. https://doi.org/10.1136/rmdopen-2017-000524
12. Lee JW, Kang JH, Yim YR, Kim JE, Wen L et al. Predictors of switching anti-tumor necrosis factor therapy in patients with ankylosing spondylitis. PLoS One 2015;10(7): e0131864. https://doi.org/10.1371/journal.pone.0131864
13. Gulyas K, Bodnar N, Nagy Z, Szamosi S, Horvath A et al. Real-life experience with switching TNF-alpha inhibitors in ankylosing spondylitis. The European Journal of Health Economics 2014; 15 (1): 93-100. https://doi.org/10.1007/ s10198-014-0598-0
14. Alazmi M, Sari I, Krishnan B, Inman RD, Haroon N. Profiling Response to TNF-Inhibitor Treatment in Axial Spondyloarthritis. Arthritis Care & Research (Hoboken) 2017; 70 (9): 1393-1399. https://doi.org/10.1002/acr.23465
15. Zurita Prada PA, Urrego Laurín CL, Guillén Astete CA, Kanaffo Caltelblanco S, Navarro-Compán V. Influence of smoking and obesity on treatment response in patients with axial spondyloarthritis: a systematic literature review. Clinical Rheumatology 2021; 40 (5): 1673-86. https://doi.org/10.1007/ s10067-020-05319-6
16. Machado P, Landewé R, Lie E, Kvien TK, Braun J et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut- off values for disease activity states and improvement scores. Annals of the Rheumatic Diseases 2011 ;70 (1): 47-53. https:// doi.org/10.1136/ard.2010.138594
17. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology 1994; 21: 2286–91.
18. Lukas C, Landewé R, Sieper J, Dougados M, Davis J et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases 2009; 68 (1): 18–24. https://doi. org/10.1136/ard.2008.094870
19. Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. The Journal of Rheumatology 1994; 21 (12): 2281–5.
20. Jones SD, Porter J, Garrett SL, Kennedy LG, Whitelock H et al. A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI). The Journal of Rheumatology 1995; 22 (8): 1609
21. Guillemin F, Briançon S, Pourel J, Gaucher A. Long-term disability and prolonged sick leaves as outcome measurements in ankylosing spondylitis. Possible predictive factors. Arthritis & Rheumatism 1990; 33 (7): 1001–6. https://doi.org/10.1002/art.1780330712
22. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis & Rheumatism 1984; 27 (4): 361-8. https://doi.org/10.1002/art.1780270401
23. Ward MM. Predictors of the progression of functional disability in patients with ankylosing spondylitis. The Journal of Rheumatology 2002; 29 (7): 1420-5.
24. Reed MD, Dharmage S, Boers A, Martin BJ, Buchanan RR et al. Ankylosing spondylitis: an Australian experience. Internal Medicine Journal 2008; 38 (5): 321-7. https://doi.org/10.1111/ j.1445-5994.2007.01471.x
25. Mattey DL, Dawson SR, Healey EL, Packham JC. Relationship between smoking and patient-reported measures of disease outcome in ankylosing spondylitis. The Journal of Rheumatology 2011; 38 (12): 2608-15. https://doi.org/10.3899/ jrheum.110641
26. Kaan U, Ferda O. Evaluation of clinical activity and functional impairment in smokers with ankylosing spondylitis. Rheumatology International 2005; 25 (5): 357-60. https://doi. org/10.1007/s00296-004-0451-3
27. Jones GT, Ratz T, Dean LE, Macfarlane GJ, Atzeni F. Disease Severity in Never Smokers, Ex-Smokers, and Current Smokers With Axial Spondyloarthritis: Results From the Scotland Registry for Ankylosing Spondylitis. Arthritis Care & Research (Hoboken) 2017; 69 (9): 1407-13. https://doi.org/10.1002/ acr.23157
28. Chen CH, Chen HA, Lu CL, Liao HT, Liu CH et al. Association of cigarette smoking with Chinese ankylosing spondylitis patients in Taiwan: a poor disease outcome in systemic inflammation, functional ability, and physical mobility. Clinical Rheumatology 2013; 32 (5): 659-63. https://doi.org/10.1007/ s10067-013-2165-y
29. Ward MM, Hendrey MR, Malley JD, Learch TJ, Davis JC et al. Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis Care & Research 2009; 61 (7): 859-66. https://doi.org/10.1002/art.24585
30. Ramiro S, Landewe R, van Tubergen A, Boonen A, Stolwijk C et al. Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. Rheumatic & Musculoskeletal Diseases Open 2015; 1 (1): e000153. https:// doi.org/10.1136/rmdopen-2015-000153
31. Fallahi S JAR, Gharibdoost F, Mahmoudi M, Ahmadzadeh N, Nicknam M H. The Correlation between Pack-Years of Smoking and Disease Activity, Quality of Life, Spinal Mobility, and Sacroiliitis Grading in Patients with Ankylosing Spondylitis. Turkish Journal of Rheumatology 2013; 28 (3): 181-8. https:// doi.org/10.5606/tjr.2013.3269
32. Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis & Rheumatism 2013; 65 (10): 2645-54. https://doi.org/10.1002/ art.38070
33. Zhao S, Yoshida K, Jones GT, Hughes DM, Tedeschi SK et al. The impact of smoking on response to TNF inhibitors in axial spondyloarthritis: methodological considerations for longitudinal observational studies. Arthritis Care & Research (Hoboken) 2019; 72 (4): 591-599. https://doi.org/10.1002/ acr.23851
34. Glintborg B, Hojgaard P, Lund Hetland M, Steen Krogh N, Kollerup G et al. Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Rheumatology (Oxford) 2016; 55 (4): 659- 68. https://doi.org/10.1093/rheumatology/kev392
35. Ciurea A, Scherer A, Weber U, Exer P, Bernhard J et al. Impaired response to treatment with tumour necrosis factor alpha inhibitors in smokers with axial spondyloarthritis. Annals of the Rheumatic Diseases 2016; 75 (3): 532-9. https:// doi.org/10.1136/annrheumdis-2013-205133
36. Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP et al. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010; 49 (3): 563- 70. https://doi.org/10.1093/rheumatology/kep422
37. Kydd AS, Chen JS, Makovey J, Chand V, Henderson L et al. Smoking did not modify the effects of anti-TNF treatment on health-related quality of life among Australian ankylosing spondylitis patients. Rheumatology (Oxford) 2015; 54 (2): 310- 7. https://doi.org/10.1093/rheumatology/keu314
38. Menegatti S, Bianchi E, Rogge L. Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses. Frontiers in Immunology 2019; 10: 382. https://doi.org/10.3389/ fimmu.2019.00382

APA	Yarkan Tuğsal H, Kenar G, can g, Çapar S, Zengin B, Akar S, Dalkılıç E, SENEL A, Koca S, Goker B, Yazici A, Inanc N, Ellidokuz H, Akkoç N, Onen F (2023). The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis. , 970 - 978. 10.55730/1300-0144.5661
Chicago	Yarkan Tuğsal Handan,Kenar Gokce,can gercek,Çapar Sedat,Zengin Berrin,Akar Servet,Dalkılıç Ediz,SENEL ABDURRAHMAN SONER,Koca Suleyman Serdar,Goker Berna,Yazici Ayten,Inanc Nevsun,Ellidokuz Hülya,Akkoç Nurullah,Onen Fatos The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis. (2023): 970 - 978. 10.55730/1300-0144.5661
MLA	Yarkan Tuğsal Handan,Kenar Gokce,can gercek,Çapar Sedat,Zengin Berrin,Akar Servet,Dalkılıç Ediz,SENEL ABDURRAHMAN SONER,Koca Suleyman Serdar,Goker Berna,Yazici Ayten,Inanc Nevsun,Ellidokuz Hülya,Akkoç Nurullah,Onen Fatos The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis. , 2023, ss.970 - 978. 10.55730/1300-0144.5661
AMA	Yarkan Tuğsal H,Kenar G,can g,Çapar S,Zengin B,Akar S,Dalkılıç E,SENEL A,Koca S,Goker B,Yazici A,Inanc N,Ellidokuz H,Akkoç N,Onen F The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis. . 2023; 970 - 978. 10.55730/1300-0144.5661
Vancouver	Yarkan Tuğsal H,Kenar G,can g,Çapar S,Zengin B,Akar S,Dalkılıç E,SENEL A,Koca S,Goker B,Yazici A,Inanc N,Ellidokuz H,Akkoç N,Onen F The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis. . 2023; 970 - 978. 10.55730/1300-0144.5661
IEEE	Yarkan Tuğsal H,Kenar G,can g,Çapar S,Zengin B,Akar S,Dalkılıç E,SENEL A,Koca S,Goker B,Yazici A,Inanc N,Ellidokuz H,Akkoç N,Onen F "The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis." , ss.970 - 978, 2023. 10.55730/1300-0144.5661
ISNAD	Yarkan Tuğsal, Handan vd. "The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis". (2023), 970-978. https://doi.org/10.55730/1300-0144.5661

APA	Yarkan Tuğsal H, Kenar G, can g, Çapar S, Zengin B, Akar S, Dalkılıç E, SENEL A, Koca S, Goker B, Yazici A, Inanc N, Ellidokuz H, Akkoç N, Onen F (2023). The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis. Turkish Journal of Medical Sciences, 53(4), 970 - 978. 10.55730/1300-0144.5661
Chicago	Yarkan Tuğsal Handan,Kenar Gokce,can gercek,Çapar Sedat,Zengin Berrin,Akar Servet,Dalkılıç Ediz,SENEL ABDURRAHMAN SONER,Koca Suleyman Serdar,Goker Berna,Yazici Ayten,Inanc Nevsun,Ellidokuz Hülya,Akkoç Nurullah,Onen Fatos The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis. Turkish Journal of Medical Sciences 53, no.4 (2023): 970 - 978. 10.55730/1300-0144.5661
MLA	Yarkan Tuğsal Handan,Kenar Gokce,can gercek,Çapar Sedat,Zengin Berrin,Akar Servet,Dalkılıç Ediz,SENEL ABDURRAHMAN SONER,Koca Suleyman Serdar,Goker Berna,Yazici Ayten,Inanc Nevsun,Ellidokuz Hülya,Akkoç Nurullah,Onen Fatos The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis. Turkish Journal of Medical Sciences, vol.53, no.4, 2023, ss.970 - 978. 10.55730/1300-0144.5661
AMA	Yarkan Tuğsal H,Kenar G,can g,Çapar S,Zengin B,Akar S,Dalkılıç E,SENEL A,Koca S,Goker B,Yazici A,Inanc N,Ellidokuz H,Akkoç N,Onen F The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis. Turkish Journal of Medical Sciences. 2023; 53(4): 970 - 978. 10.55730/1300-0144.5661
Vancouver	Yarkan Tuğsal H,Kenar G,can g,Çapar S,Zengin B,Akar S,Dalkılıç E,SENEL A,Koca S,Goker B,Yazici A,Inanc N,Ellidokuz H,Akkoç N,Onen F The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis. Turkish Journal of Medical Sciences. 2023; 53(4): 970 - 978. 10.55730/1300-0144.5661
IEEE	Yarkan Tuğsal H,Kenar G,can g,Çapar S,Zengin B,Akar S,Dalkılıç E,SENEL A,Koca S,Goker B,Yazici A,Inanc N,Ellidokuz H,Akkoç N,Onen F "The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis." Turkish Journal of Medical Sciences, 53, ss.970 - 978, 2023. 10.55730/1300-0144.5661
ISNAD	Yarkan Tuğsal, Handan vd. "The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis". Turkish Journal of Medical Sciences 53/4 (2023), 970-978. https://doi.org/10.55730/1300-0144.5661